IFN signaling is associated with radiotherapy response in malignant peripheral nerve sheath tumors. Read more about IFN signaling is associated with radiotherapy response in malignant peripheral nerve sheath tumors.
Patient-Derived Xenograft Models of Fanconi Anemia-Associated Head and Neck Cancer Identify Personalized Therapeutic Strategies. Read more about Patient-Derived Xenograft Models of Fanconi Anemia-Associated Head and Neck Cancer Identify Personalized Therapeutic Strategies.
The 2025 Nobel Prize in Physiology or Medicine - a bridge to peripheral immune tolerance. Read more about The 2025 Nobel Prize in Physiology or Medicine - a bridge to peripheral immune tolerance.
A20's linear ubiquitin-binding motif restrains pathogenic activation of Th17 cells and IL-22-driven enteritis. Read more about A20's linear ubiquitin-binding motif restrains pathogenic activation of Th17 cells and IL-22-driven enteritis.
Clonal expansion of alveolar fibroblast progeny drives pulmonary fibrosis in mouse models. Read more about Clonal expansion of alveolar fibroblast progeny drives pulmonary fibrosis in mouse models.
Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis. Read more about Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis.
Corrigendum to Identification of CD84 as a potent survival factor in acute myeloid leukemia. Read more about Corrigendum to Identification of CD84 as a potent survival factor in acute myeloid leukemia.
Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS. Read more about Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS.
PROX1 is an early driver of lineage plasticity in prostate cancer. Read more about PROX1 is an early driver of lineage plasticity in prostate cancer.
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer. Read more about Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.
